Aarhus, Denmark (UroToday.com) Dr. David Krantz from Umea University in Sweden presented data investigating the effect of neoadjuvant cisplatin-based chemotherapy on T cell phenotypes within the sentinel nodes of muscle invasive bladder cancer (MIBC) patients. A cohort of 27 patients who received neoadjuvant chemotherapy (NAC) followed by sentinel-node dissection and radical cystectomy (RC) were identified and compared with 13 NAC-naïve patients who underwent sentinel node detection and RC only. Dr. Krantz reported that T cells from the sentinel nodes and peripheral blood were analyzed using flow cytometry. NAC exposure was found to be associated with increased CD8+ toxicity, and activation of tumor specific CD4+ tumor effector cells. Concurrently, cisplatin-based NAC was reported to inhibit regulatory T cell activity. These data have been published in European Urology.1
Abstract take home message:
- NAC reinforces the anti-tumor immune response by activating the effector arm of the T cells and diminishing the influence of suppressive regulatory T cells.1
Presented by: David Krantz, MD, PhD, Unit of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
Written by Dr. Vikram M. Narayan (@VikramNarayan), Urologic Oncology Fellow with Ashish M. Kamat, MD (@UroDocAsh), Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX at the 17th meeting of the International Bladder Cancer Network, (IBCN, #IBCN2019) October 3rd – 5th, 2019 in Aarhus, Denmark.